Elsubrutinib,Upadacitinib,ABBV-599
AbbVie
['upadacitinib', 'abbvie']
upadacitinib improved sle disease activity and time-to-first flare while lowering the need for steroids, showed data shared at #eular2023. developed by abbvie, upadacitinib is approved for several autoimmune diseases and in phase 3 trials for #sle. 
The Lupus Research Alliance is the world’s largest private funder of lupus research. Together with your help, we will conquer lupus.